Özlem ÖZAKPINAR, Şule YAVUZ, Nahit RİZANER, K. Turay YARDIMCI, Murat DIŞBUDAK, Kaysu ÖZALTUN, Şermin TETİK

In vivo effect of colchicine, colchicine and anti- aggregating agent on protein oxidation in Behcet's Disease

Amaç. Behçet hastalığı (BH), kronik, sistemik bir enflamatuar hastalıktır. Oksidatif stres plazmaprotein modifikasyonlarıyla ilişkilidir ve Behçet hastalığının gelişiminde önemli rol oynayabilir.Bu çalışmada, Behçet hastalığında geliştiği düşünülen oksidatif hasarın plazma proteinlerineetkisinin belirlenmesi ve tedavide kullanılan kolşisin ve antiagregan ilaçların oksidatifhasara/cevaba etkisinin protein kantitasyonu yapılarak değerlendirilmesi amaçlanmıştır. Yöntem.Çalışmaya 45 Behçet hastası ve 40 kontrol grubu dahil edildi. Çalışma grupları, Grup I: hiç ilaçkullanmayan inaktif durumdaki hastalar; Grup II, yalnız kolşisin kullanan (1,0-2,0 mg/gün) veGrup III, aktif durumdaki kolşisin ve antiagregan (asetil salisilik asid 100 mg/gün) kullananhastalar. Plazma total protein, plazma karbonil, total tiyol seviyeleri, ESR ve CRP seviyeleribelirlendi. Protein pik alanları yüksek basınçlı sıvı kromatografisi ile analiz edildi. Bulgular.Plazma protein düzeyleri kontrollarla karşılaştırıldığında Grup I ve IIde anlamlı derecedeyüksekti. Plazma karbonil düzeyleri kontrollere göre Grup I, II ve IIIde anlamlı derecedeyüksekti. Kolşisin ve antiagregan tedavisi sonrası Grup IIIde karbonil düzeyleri anlamlı derecededüşerken plasma tiyol düzeyleri anlamlı derecede yüksek bulundu. Plazma CRP ve ESRdüzeylerinin tedaviye cevapları Grup IIIde diğer gruplarla karşılaştırıldığında anlamlı derecedepozitif bulundu. Plazma protein fragmantasyonu Behçet Hastalarında tespit edilmedi. Sonuç.Oksidatif strese bağlı olarak gelişen plazma protein modifikasyon verileri Behçet hastalığınınpatofizyolojisinde çok değerli olabilir. Hastalığın şiddeti ve oksidatif stresin yaygınlığı arasındakiilişki de gözönüne alındığında çok merkezli ve uzun dönem klinik takiplerin olduğu çalışmalarınyapılması gerekmektedir.

Behçet hastalığında kolşisin, kolşisin ve antiagregan aj anın p rotein oksidasyonu üzerine in vivo etkileri

Aim. Behcet s Disease is a chronic, systemic inflammatory disease. Oxidative stress related toplasma protein modifications may have an important role in the progression of Behcet s Disease.In this study the effect of oxidative damage during the course of Behcet s disease on plasmaproteins and the effect of colchicine and anti-aggregating agents on prevention or depression ofoxidative damage was evaluated by plasma protein characterization and quantitation. Methods. 45Behcet s Disease and 40 control subjects were included in this study. Study groups are determinedas Group I: in inactive stage receiving no drugs, Group II: active stage receiving only colchicine(1.0-2.0 mg/day), and Group III: in active stage receiving colchicine and antiagregating agent(acetyl salycilic acid 100 mg/day). Plasma total protein, plasma carbonyl content, plasma totalthiol levels were determined spectrophotometrically. Erythrocyte sedimentation rate (ESR) and C- reactive protein (CRP) were evaluated by conventional methods. The protein peak areas wereanalyzed through high pressure liquid chromatography (HPLC). Results. Plasma protein levelswere significantly higher in Group I and Group II compared to controls. Plasma carbonyl levelswere higher in Group I, II and III than the control groups. After colchicine ve antiaggregatingagent treatment in patient groups plasma carbonyl and were found significantly lower whereasthiol levels were found significantly higher in Group III than the other patient groups. Respons ofplasma CRP and ESR levels to treatment in Group III were significantly positive compared to theother groups. Plasma protein fragmantation was not dedected in Behcet s diseases. Conclusion.The plasma protein data which developed upon oxidative stress is very valuable inphysiopathology of Behcet s Disease. When the relation between severity of the disease and theextent of oxidative stress is considered, multicentral and longterm clinical follow ups could beproposed.

PDF

___

1. Behçet H. Über rezidivierende, apththöse, durch ein virus verursachte geschwüre am munt, am auge und an den genitalien. Dermatol Wochenschr 1937; 105: 1152-7.
2. Mizushima Y, Matsuda T, Hoshi K, Ohno S. Induction of Behçets disease symptoms after dental treatment and streptococcal antigen skin test. J Rheumatol 1988; 15: 1029-30.
3. Sun A, Chang JG, Kao CL, Liu BY, Wang JT, Chu CT, Yuan JH, Chiang CP. Human cytomegalovirus as a potential etiologic agent in recurrent aphthous ulcers and Behçet's disease. J Oral Pathol Med 1996; 25: 212-8.
4. Lehner T. Immunopathogenesis of Behçets disease. Ann Med Interne 1999; 150: 483-7.
5. Mizuki N, Ohno S. Immunogenetic studies of Behçets disease. Rev Rhum 1996; 63: 520-7.
6. Gul A. Standard and novel therapeutic approaches to Behçet's disease. Drugs 2007; 67: 2013-22.
7. Halliwell B, Gutteridge JM, Cross CE. Free radicals, antioxidants, and human disease: where are we now? J Lab Clin Med 1992; 119: 598-620.
8. Köse K, Yazici C, Cambay N, Aşcioğlu O, Doğan P. Lipid peroxidation and erythrocyte antioxidant enzymes in patients with Behçet's disease. Tohoku J Exp Med 2002; 197: 9-16.
9. Yapışlar H, Aydoğan S, Aşçıoğlu Ö. Behçet hastalığında artan oksidatif stresin eritrosit deformabilitesi üzerine olan etkisi. Erciyes Tıp dergisi 2006; 28:197-204.
10. Orem A, Efe H, Değer O, Cimşit G, Uydu HA, Vanizor B. Relationship between lipid peroxidation and disease activity in patients with Behçet's disease. J Dermatol Sci 1997; 16: 11-6.
11. Kaya S, Köse K, Yazıcı C, Utaş S, Borlu M. Pirrolize Protein Behçet Hastalığında Yeni Bir Oksidatif Stres Belirteci Olabilir mi? Erciyes Tıp Dergisi 2010; 32: 1-4.
12. Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease. Lancet 1990; 335: 1078-80.
13. Gambino SR, DiRe JJ, Monteleone M, Budd DC. The westergren sedimentation rate, using k3edta. Tech Bull Regist Med Technol 1965; 35: 1-8.
14. Lowry OH, Rosebrough HJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-75.
15. Pearle AD, Scanzello CR, George S, Mandl LA, DiCarlo EF, Peterson M, Sculco TP, Crow MK. Elevated high-sensitivity C-reactive protein levels are associated with local inflammatory findings in patients with osteoarthritis. Osteoarth Carthilage 2007; 5: 516-23.
16. Levine RL, Garland D, Oliver CN, Amici A, Climent I, Lenz AG, Ahn BW, Shaltiel S, Stadtman ER. Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol. 1990; 186: 464-78.
17. Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys 1959; 82: 70-7.
18. Tetik S, Kaya K, Yardimci T. Effect of oxidized fibrinogen on hemostatic system: in vitro study. Clin Appl Thromb Hemost 2011; 17: 259-63.
19. Dalle-Donne I, Rossi R, Giustarini D, Milzani A, Colombo R. Protein carbonyl groups as biomarkers of oxidative stress. Clin Chim Acta. 2003; 329: 23-38.
20. Bang D, Choi B, Kwon HJ, Lee ES, Lee S, Sohn S. Rebamipide affects the efficiency of colchicine for the herpes simplex virus-induced inflammation in a Behcet's disease mouse model. Eur J Pharmacol 2008; 598: 112-7.
21. Pronai L, Ichikawa Y, Ichimori K, Nakazawa H, Arimori S. Association of enhanced superoxide generation by neutrophils with low superoxide scavenging activity of the peripheral blood, joint fluid, and their leukocyte components in rheumatoid arthritis: effects of slow-acting anti-rheumatic drugs and disease activity. Clin Exp Rheumatol 1991; 9: 149-55.
22. Arca E, Gür AR. Behçet hastalığı. T Klin Tıp Bilimleri 2003; 23: 261-8.
23. Sun A, Wang YP, Chia JS, Liu BY, Chiang CP.Treatment with levamisole and colchicine can result in a significant reduction of IL-6, IL-8 or TNF-alpha level in patients with mucocutaneous type of Behcet's disease. J Oral Pathol Med 2009; 38: 401-5.
24. Yazici H. Behçets syndrome (the vasculitides). In: Klippel JH, Dieppe PA, eds. Rheumatology. London: Mosby Year Book Europe, 1994; 6: 1-6.
25. Tetik S, Ahmad S, Alturfan AA, Fresko I, Disbudak M, Sahin Y, Aksoy H, Yardimci KT. Determination of oxidant stress in plasma of rheumatoid arthritis and primary osteoarthritis patients. Indian J Biochem Biophys 2010; 47: 353-8.
26. Bekpınar S, Kılıç N, Ünlüçerçi Y, Akdağ Köse A. Oxidant/antioxidant status in patients with Behcet Disease. Macedonian Med Sci 2010; 15: 37-42.
27. Kökçam I, Naziroglu M. Effects of vitamin E supplementation on blood antioxidants levels in patients with Behçet's disease. Clin Biochem 2002; 35: 633-9.
28. Yağcı R, Özyurt H, Akbaş A, Aydın B, Özlük E, Ekşioğlu M, Totan Y. Behçet hastalığında toplam antioksidan kapasite, toplam oksidan durum ve dehidroepiandrosteron sülfat düzeyleri. Ret-Vit 2007; 15: 263-6.
29. Orem A, Yandi YE, Vanizor B, Cimşit G, Uydu HA, Malkoç M. The evaluation of autoantibodies against oxidatively modified low-density lipoprotein (LDL), susceptibility of LDL to oxidation, serum lipids and lipid hydroperoxide levels, total antioxidant status, antioxidant enzyme activities, and endothelial dysfunction in patients with Behçet's disease. Clin Biochem 2002; 35: 217-24.
30. Kandi B, Cicek D, Ilhan N. Vitamin levels in Behçet's disease. J Dermatolog Treat 2007; 18: 69-75.
31. Evereklioglu C, Er H, Turkoz Y, Cekmen M. Serum levels of TNF-alpha, sIL- 2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet's disease. Mediators Inflamm 2002; 11: 87-93.
32. Fujiwara Y, Kondo T, Murakami K, Kawakami Y. Decrease of the inhibition of lipid peroxidation by glutathione-dependent system in erythrocytes of non-insulin dependent diabetics. Klin Wochenschr 1989; 67: 336-41.
33. Tetik S, Uras F, Yardimci KT. Protein Oxidation: basic weiev on characterization, detection and consequences. Adv Mol Med 2007; 3: 63-7.
34. Saba D, Saricaoğlu H, Bayram AS, Erdoğan C, Dilek K, Gebitekin C, Ozkan H, Ozer ZG. Arterial lesions in Behçet's disease. Vasa 2003; 32: 75-81.
35. Can M, Direskeneli H. Behçet hastalarında kas, iskelet sistemi ve damar tutulumu. Turkderm 2009; 2: 54-60.
36. Karadağ R, Koca C, Totan Y, Yağcı R, Aydın M, Karadağ A S, Akbay G, Ekşioğu M, Yiğitoğlu R. Comparison of serum levels of IL-6, IL-8, TNF-α, C reactive protein and heat shock protein 70 in patients with active or inactive Behcets disease. Turk J Med Sci 2010; 40: 57-62.